Overview
Deb Muoio is professor in the Departments of Medicine and Pharmacology & Cancer Biology, George Barth Geller Distinguished Professor of Cardiovascular Disease, and Associate Director of the Duke Molecular Physiology Institute (DMPI). She is viewed nationally and internationally as a leader in the fields of diabetes, obesity, exercise physiology, and mitochondrial energy metabolism. Her laboratory investigates mechanisms of metabolic regulation, with emphasis on molecular events that link lifestyle factors such as over nutrition and physical inactivity to metabolic disorders, including obesity, diabetes, and heart failure. Her program features a translational approach that combines work in animal and cell-based models with human studies, using genetic engineering, molecular biology and mass spectrometry-based metabolomics and proteomics as tools to understand the interplay between mitochondrial physiology and cardiometabolic health. Her laboratory developed a sophisticated platform for deep and comprehensive assessment of mitochondrial bioenergetics and energy transduction. Her team is integrating this new platform with metabolomics, proteomics, and metabolic flux analysis to gain insights into mechanisms by which mitochondria modulate insulin action and metabolic resilience. She has published more than 120 papers in prominent journals such as Cell, Cell Metabolism, Circulation, Circulation Research, Diabetes, and JCI Insight. Dr. Muoio’s laboratory has enjoyed longstanding support from the NIDDK and NHLBI.
Current Appointments & Affiliations
Recent Publications
Abstract Wed007: Postnatal loss of the nuclear receptor PPARα in cardiomyocytes promotes glycolytic remodeling and cardiomyocyte dedifferentiation via Fbp2 downregulation
Conference Circulation Research · August 2025 Cardiomyocytes (CMs) undergo metabolic and contractile reprogramming during cardiac stress and injury. This reprogramming response includes a fuel metabolic shift to a more fetal-like or immature state with downregulation in fatty acid ... Full text Cite212-OR: Hepatic Overexpression of ACSS3 Alters Glucose Control and Fatty Acid Metabolism in Lean Mice
Conference Diabetes · June 20, 2025 Introduction and Objective: Short chain fatty acids (SCFAs) are associated with adverse metabolic outcomes; however, little is known about their link to metabolic disease. Emerging evidence suggests that in addition to acting as signaling molecules ... Full text CiteKetogenesis mitigates metabolic dysfunction-associated steatotic liver disease through mechanisms that extend beyond fat oxidation.
Journal Article J Clin Invest · June 16, 2025 The progression of metabolic dysfunction-associated steatotic liver disease (MASLD) to metabolic dysfunction-associated steatohepatitis (MASH) involves alterations in both liver-autonomous and systemic metabolism that influence the liver's balance of fat a ... Full text Link to item CiteRecent Grants
iPediHeart: Interdisciplinary Research Training Program for Pediatric Heart Disease
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2025 - 2030Endocrinology and Metabolism Training Program
Inst. Training Prgm or CMEMentor · Awarded by National Institute of Diabetes and Digestive and Kidney Diseases · 2024 - 2029The Effect of Exercise on T Cell Aging in Rheumatoid Arthritis
ResearchCo-Mentor · Awarded by National Institute on Aging · 2024 - 2029View All Grants